Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M

Metagenomi Therapeutics, Inc.

Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.
Cash, equivalents, and marketable securities $226.0M as of Mar 31, 2025; runway into 2027.
R&D expenses $25.1M (Q1 2025) vs $31.4M (Q1 2024); G&A $6.8M vs $8.8M.
Published novel compact CRISPR-associated transposases in Nature Communications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.